Inbuild subgroup analysis
WebAlthough the INBUILD trial was not designed or powered to evaluate individual ILDs, subgroup analyses suggested that there was no heterogeneity in the rate of decline in FVC in the placebo... WebNov 22, 2007 · Pocock SJ, Assmann SF, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and …
Inbuild subgroup analysis
Did you know?
WebJun 4, 2024 · The RA-ILD subgroup represented 13.4% of those randomized in INBUILD. The mean time since diagnosis of RA was about 10 years. More than 60% were smokers or … WebMar 9, 2024 · In conclusion, these analyses of data from the INBUILD trial suggest that in subjects with PPF, lower BMI at baseline and weight loss may be associated with worse outcomes. ... Statistics in medicine–reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94. Article CAS PubMed Google Scholar European Medicines …
WebMay 2, 2024 · In subgroup analyses, the interaction P value was an indicator of the potential heterogeneity in the treatment effect of nintedanib versus placebo across the subgroups (i.e., a P value more than 0.05 indicated that there was no evidence that the treatment effect differed across the subgroups). WebBackground: In the INBUILD trial, nintedanib slowed the rate of decline in FVC over 52 weeks vs placebo in subjects with non-IPF progressive fibrosing ILDs. Subjects were required to have an FVC ≥45% predicted at baseline. Aim: To assess the effect of nintedanib on FVC decline in subjects with differing FVC at baseline in the INBUILD trial. Methods: The rate …
WebCO-INFECTION OF ESCHERICHIA COLI PATHOTYPES WITH INTESTINAL PARASITES WebApr 6, 2024 · Subgroup analysis of the INBUILD study did not show substantial differences in the effect of nintedanib versus placebo among patients with progressive FHP.30 Yet, …
WebApr 14, 2024 · ctd-ild该抗纤维化治疗吗？｜cts20242024-12-14来源：医学界呼吸频道 cts20248 条内容 ·1273人看过 . 结缔组织病（ctd）是一组全身性自身免疫性疾病，病变可累及多种脏器，以肺脏受累最为常见。
WebN2 - Background: The efficacy of nintedanib in progressive fibrosing interstitial lung diseases (ILDs) was demonstrated in the randomised, double-blind, placebo-controlled INBUILD trial. This subgroup analysis evaluated the efficacy and safety of nintedanib in the Japanese population. great research paperWebIn subgroup analyses, the interaction P value was an indicator of the potential heterogeneity in the treatment effect of nintedanib versus placebo across the subgroups (i.e., a P value … great research paper topics for collegeWebNov 1, 2024 · A previous subgroup analysis of data from the INBUILD trial showed that nintedanib reduced the annual rate of decline in forced vital capacity (FVC) in Japanese … great research potentialWebMethods: Patients with a physician-diagnosed ILD other than IPF were eligible to participate in the INBUILD trial if they had features of diffuse fibrosing lung disease of >10% extent on HRCT, forced vital capacity (FVC) ≥45% predicted, diffusing capacity of the lungs for carbon monoxide (DLco) ≥30–< 80% predicted, and met ≥1 of 4 ... floor warming wireWebFeb 23, 2024 · The INBUILD trial enrolled subjects with a fibrosing ILD other than idiopathic pulmonary fibrosis, with diffuse fibrosing lung disease of >10% extent on high-resolution computed tomography, forced vital capacity (FVC) ≥45% predicted and diffusing capacity of the lungs for carbon monoxide ≥30%–<80% predicted. great research topicsWebA post hoc subgroup analysis of the INBUILD® trial data was used to evaluate the treatment effect (annual rate of FVC decline) of OFEV in patients with underlying autoimmune … great research topics 2021WebApr 12, 2024 · Idiopathic Pulmonary Fibrosis. Idiopathic pulmonary fibrosis is the most common type of idiopathic interstitial pneumonia. It is defined as a specific form of … floor warming carpet tiles